Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Jul;66(4):323–334. doi: 10.1016/j.curtheres.2005.08.009

Evaluation of a new five-injection, two-site,intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India

MK Sudarshan 1,*, SN Madhusudana 2, BJ Mahendra 1, DH Ashwath Narayana 1, MS Ananda Giri 1, O Popova 3, HB Vakil 4
PMCID: PMC3964532  PMID: 24672132

Abstract

Background:

Human rabies is an ongoing significant public health problem inmany developing countries, with India reporting the highest incidence of rabies-related deaths (∼20,000 per year). Many people living in India cannot afford the standard IM postexposure prophylaxis (PEP) with cell-culture vaccines, which are administered using a 5-dose regimen developed in Essen, Germany. A potentially less expensive intradermal (ID) regimen, based on the Essen regimen, has been developed at the Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India.

Objective:

The objective of this study was to compare the immunogenicity and local and systemic tolerability of the KIMS-1D regimen with those of the standard Essen IM regimen in healthy adult volunteers in India.

Methods:

This randomized, open-label, active-controlled trial was conductedat the Antirabies Clinic, Medical College, KIMS. Healthy adult volunteers were randomly assigned to receive purified chick embryo cell vaccine (PCECV) using the KIMS-1D regimen (0.1 mL injected ID at 2 body sites on days 0, 3, 7, 14, and 28 [“2-2-2-2-2”]) or the Essen IM regimen (1 mL injected IM at 1 body site on the same days Subjects were followed up for 365 days by the treating physician and encouraged to voluntarily report any adverse events (AEs). Serum rabies virus-neutralizing antibody (RVNA) concentrations were measured before the first injection on day 0 (baseline) and on days 14, 28, 90, 180, and 365, using the rapid fluorescent focus inhibition test.

Results:

Ninety-one subjects were enrolled and included in the tolerabilityand immunogenicity analyses. The ID group comprised 45 subjects (26 men, 19 women; mean [SD] age, 20.84 [1.48] years); the IM group, 46 subjects (28 men, 18 women; mean [SD] age, 21.02 [1.16] years). The most common local AEs were pain at the injection site (2/225 [0.9%] in the ID group and 10/230 [4.3%] in the IM group; P < 0.006) and itching at the injection site (5/225 [2.2%] in the ID group and none in the IM group; P = 0.026). All of the AEs were transient and resolved without the need for medication. All subjects had serum RVNA concentrations ≥0.5 IU/mL—considered protective by the World Health Organization—at all follow-up visits. However, the mean RVNA concentrations in the IM group were significantly higher compared with those in the ID group from days 14 to 365 (all, P < 0.001).

Conclusion:

In this study in healthy volunteers, PEP with PCECV administered using the KIMS-ID regimen was well tolerated and immunologically efficacious for 365 days. Adequate RVNA levels were maintained with the KIMS-ID regimen from days 14 to 365, although these levels were significantly lower than those achieved in the group receiving the Essen IM regimen (all, P < 0.001).

Key words: rabies, intradermal rabies vaccination, KIMS-ID regimen, randomizedcontrolled trial

Full Text

The Full Text of this article is available as a PDF (638.5 KB).

References

  • 1.World Health Organization, Department of Communicable Disease Surveillance and Response . WHO; Geneva, Switzerland: 1999. World Survey for Rabies No. 33 for the year 1997 [WHO Web site]http://www.who.int Publication no. WHO/CDS/CSR/APH/99.4. Available at: Accessed June 1, 2005. [Google Scholar]
  • 2.Association for the Prevention and Control of Rabies in India. Assessing the burden of rabies in India: A national multicentric survey. Progress Report. 2003. Available at: www.vet.ed.ac.uk. Accessed June 1, 2005.
  • 3.Bhalla S., Nagar S. Analysis of complications of nervous tissue anti-rabies vaccines in Jamnagar, Gujarat. Ind J Int Med. 2001;11:13–16. (Suppl) [Google Scholar]
  • 4.Singh S., Kumar T. Rabies vaccines-An overview. J APCRI. 1999;1:14–20. [Google Scholar]
  • 5.World Health Organization . Expert Committee on Rabies. WHO; Geneva, Switzerland: 1984. http://www.cdc.gov/mmwr 7th report [CDC Web site] Accessed June 1, 2005. Accessed June 1, 2005. Accessed June 1, 2005. [Google Scholar]
  • 6.Rabies prevention-United States, 1984. MMWR Morb Mortal Wkly Rep. 1984;33:393–402. [PubMed] [Google Scholar]; Rabies prevention-United States, 1984. MMWR Morb Mortal Wkly Rep. 1984;33:407–408. [PubMed] [Google Scholar]
  • 7.World Health Organization . Expert Committee on Rabies. WHO; Geneva, Switzerland: 1992. http://www.cdc.gov/mmwr (Technical Report Series 824). 8th report [CDC Web site] Accessed June 1, 2005. Accessed June 1, 2005. Accessed June 1, 2005. [PubMed] [Google Scholar]
  • 8.Chutivongse S., Wilde H., Supich C. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet. 1990;335:896–898. doi: 10.1016/0140-6736(90)90488-q. [DOI] [PubMed] [Google Scholar]
  • 9.Briggs D.J., Banzhoff A., Nicolay U. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ. 2000;78:693–698. [PMC free article] [PubMed] [Google Scholar]
  • 10.Madhusudana S.N., Anand N.P., Shamsundar R. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for postexposure prophylaxis for rabies. Natl Med J lndia. 2001;14:145–147. [PubMed] [Google Scholar]
  • 11.Jaiiaroensup W., Lang J., Thipkong P. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally (Results of a prospective randomized trial) Vaccine. 1998;16:1559–1562. doi: 10.1016/s0264-410x(98)00045-0. [DOI] [PubMed] [Google Scholar]
  • 12.Association for Prevention and Control of Rabies in India. In: Proceedings of the National Seminar on Intradermal Rabies Vaccination. February 25, 2003; Bangalore, India.
  • 13.Khawplod P., Tantawichien T., Wilde H. Use of rabies vaccines after reconstitution and storage. Clin Infect Dis. 2002;34:404–406. doi: 10.1086/324507. [DOI] [PubMed] [Google Scholar]
  • 14.World Health Organization . WHO Expert Consultation on Rabies. WHO; Geneva, Switzerland: 2004. http://www.who.int/rabies (Technical Report Series 931 [WHO Web site]). Available at: Accessed June 1, 2005. [Google Scholar]
  • 15.European Agency for the Evaluation of Medicinal Products . International Conference on Harmonisation-World Health Organization. WHO; Geneva, Switzerland: 2002. http://www.emea.eu.int. (Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6). Available at: Accessed June 1, 2005. [Google Scholar]
  • 16.Smith J.S., Yager P.A., Baer G.M. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus neutralizing antibody. In: Meslin F.-X., Kaplan M.M., Koprowsky H., editors. Laboratory Techniques in Rabies. 4th ed. World Health Organization; Geneva, Switzerland: 1996. pp. 181–192. [Google Scholar]
  • 17.Madhusudana S.N., Sanjay T.V., Mahendra B.J., Suja M.S. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen. Int JInfect Dis. 2004;8:175–179. doi: 10.1016/j.ijid.2003.07.001. [DOI] [PubMed] [Google Scholar]
  • 18.World Health Organization . Department of Communicable Disease Surveillance and Response. WHO; Geneva, Switzerland: 1988. http://www.who.int/en (WHO Recommendations on Rabies Post-Exposure Treatment and the Correct Technique of Intradermal Immunization Against Rabies [WHO Web site]). Publication no. WHO/EMC/Z00 96.6. Available at: Accessed August 1, 2005. [Google Scholar]
  • 19.Sabchareon A., Chantavanich P., Pasuralertsakul S. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations withpurified Vero cell rabies vaccine. Pediatr Infect Dis J. 1998;17:1001–1007. doi: 10.1097/00006454-199811000-00007. [DOI] [PubMed] [Google Scholar]
  • 20.Yang Y., Zhang J. An experimental study on the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. J Epidemiol. 1999;9:209–215. doi: 10.2188/jea.9.209. [DOI] [PubMed] [Google Scholar]
  • 21.Beran J., Honegr K., Banzhoff A., Malerczyk C. Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: Investigation of the immunogenicity ofserially diluted purified chick embryo cell rabies vaccine. Vaccine. 2005;23:3902–3907. doi: 10.1016/j.vaccine.2005.03.007. [DOI] [PubMed] [Google Scholar]
  • 22.Sudarshan M.K., Mahendra B.J., Ashwath Narayana D.H. A cost accounting analysis of production of Semple (sheep brain) vaccine in India. Journal of Association for Prevention and Control of Rabies in India. 2002;4:40–41. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES